EXOZ (32) ESLA (39) ALGS (22) MGX (24) ⌘ Pro Terminal →

Elutia Inc. (Class A) (ELUT) — RQD Stock Rating Cockpit

$0.81 -3.13% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.80

Elutia Inc. (Class A) (ELUT) receives a Roarable Rating of E (Strong Sell) and flashes a Red SELL / AVOID rating (31/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+296.7% (NI vs OCF)).

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $36.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ELUT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Elutia Inc. (Class A) (NASDAQ: ELUT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.81 (-3.13% 1D, market cap $36.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 7/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 7/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ELUT compare to EXOZ and ESLA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELUT carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 53.7%, and ROIC of -35.0%. By comparison, EXOZ (eXoZymes Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $38.2M) and ESLA (Estrella Immunopharma Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $31.7M). Among the 5-stock peer group, ELUT leads on earnings multiple (N/A) while ELUT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ELUT?

▼

Per ELUT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001708527), Elutia Inc. (Class A) generated $12.3M in revenue (-15.0% YoY), $53.4M in net income, and -$46.7M in free cash flow against $62.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.80 (-0.75%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ELUT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY ELUT SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+7/20 pts (23% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.79+2.5% Next Q

Q2 (-2Q)

Grade E$0.81-1.2% Next Q

Q3 (-1Q)

Grade E$0.80+1.3% Next Q

Current

Grade E$0.81-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ELUT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ELUT currently carries a cautious 31/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.83) and Max Pain ($0.85) forces dealer call-delta covering toward $1.45.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ELUT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ELUT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

48.830 Oversold · 70 Hot

ALTMAN-Z SHIELDDISTRESS RISK (<1.8)

0.20>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE35% OF RANGE

L: $1$0.81H: $1

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 0 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● FORENSIC WATCH

SEC fine-print scan & interest-rate fit

Our SEC fine-print scanner flagged elevated accounting or executive-hedging risk combined with interest-rate headwinds.

Factor Grade: D-RQD 14 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ELUT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (15)

-35.0% ROIC with 53.7% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (35)

SEC filing audit notes an accounting accrual divergence or executive risk-factor disclosure — monitor upcoming 10-Q/10-K filings.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

17/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like ELUT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion.
!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ELUT)

✓Walkthrough of ELUT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ELUT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.80%▼ DESCENDING CHANNEL

2026-11-02O $0.84H $0.84L $0.81C $0.81VOL 56.0K

RES: $0.87SUP: $0.61SMA50: $0.83SMA200: $0.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ELUT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ELUT Butterfly Map → + Track ELUT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ELUT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ELUT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ELUT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ELUT)

Health Care Rank #822 of 1016 ⚔️ EXOZ vs ELUT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ELUT vs. EXOZ, ESLA, ALGS, MGX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Elutia Inc. (Class A) (ELUT) ranks #822 by composite RQD confidence (31/100, grade E) and #786 by equity capitalization ($36.0M). Within this direct 5-issuer industry benchmark cohort, ELUT leads on earnings valuation at N/A trailing P/E, while ELUT leads on capital efficiency and profitability with -35.0% ROIC and 53.7% gross margin. ESLA currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with ELUT at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ELUT ACTIVE Elutia Inc. (Class A)	E	31/100	—	53.7%	-35.0%	-3.13%	$36.0M	Benchmark Subject
EXOZ eXoZymes Inc.	E	32/100	—	—	-35.0%	-2.72%	$38.2M	/exoz-vs-elut →
ESLA Estrella Immunopharma Inc.	D-	39/100	—	—	-35.0%	-11.32%	$31.7M	/esla-vs-elut →
ALGS Aligos Therapeutics Inc.	E	22/100	—	—	-35.0%	-2.71%	$31.4M	/algs-vs-elut →
MGX Metagenomi Therapeutics Inc.	E	24/100	—	—	-35.0%	+1.03%	$31.4M	/mgx-vs-elut →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001708527

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elutia Inc. (Class A) (ELUT) reported GAAP revenue of $12.3M (-15.0% vs. FY2024 revenue of $14.5M ) , GAAP net income of $53.4M, operating cash flow of -$44.8M, and free cash flow of -$46.7M (-100.3% YoY). On the balance sheet, ELUT closed FY2025 with $62.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$12.3M	$53.4M	-$44.8M	-$46.7M	$62.4M	—
FY2024 (FY)	2024-12-31	$14.5M	-$53.9M	-$22.7M	-$23.3M	$36.1M	$22.6M
FY2023 (FY)	2023-12-31	$0	-$37.7M	-$21.8M	-$21.8M	—	—

3. ELUT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ELUT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ELUT compare to EXOZ and ESLA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ELUT?

Where is ELUT trading relative to its 50-day, 200-day, and 52-week technical levels?

ELUT last traded at $0.81 (-3.13% on volume of 56,045 shares), positioning the stock -2.41% below its 50-day simple moving average ($0.83) and -16.49% below its 200-day simple moving average ($0.97). Across its 52-week range of $0.50 to $1.38, ELUT sits at the 35.2% percentile with a 14-day RSI of 48.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.91).

ELUT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ELUT stock right now?

Elutia Inc. (Class A) (ELUT) currently earns a Roarable Rating of E (Strong Sell — SELL) with 31/100 RQD Confidence. Weak 31/100 RQD score compounded by SEC accrual divergence (+296.7% (NI vs OCF)).

What is ELUT's 12-month price target and RQD AI Jury consensus?

ELUT's 12-month base price target is $0.71 (range $0.55 to $1.45), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ELUT RQD Cockpit ELUT 12M Forecast ELUT Earnings & Move ELUT Dividends & DRIP ELUT Insiders & 13F ELUT Whale Options ELUT Profit Sankey ELUT News & Why